RPT-Pfizer-Allergan sparks fresh tax inversion angst on Capitol Hill
October 30, 2015 at 07:55 AM EDT
WASHINGTON, Oct 29 (Reuters) - Pfizer Inc faces political risks in Washington if it proceeds with a bid for Allergan, but with little chance of legislation to curb such tax inversion deals, the Obama administration may be able to throw up only limited obstacles.
